Skip to main content
SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD logo

SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000078 ISIN · CNE000000X95 LEI · 300300J4GCOV7CYQTB51 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,619 across all filing types
Latest filing 2021-01-28 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 000078

About SHENZHEN NEPTUNUS BIOENGINEERING CO.,LTD

https://www.neptunusbio.com

Shenzhen Neptunus Bioengineering Co., Ltd. is a comprehensive healthcare enterprise focused on the research, development, manufacturing, and distribution of pharmaceutical products. The company operates across the entire industry value chain, including the production of chemical drugs, biological preparations, and traditional Chinese medicines. Its portfolio extends to medical devices and health supplements. A significant component of its operations involves a large-scale pharmaceutical distribution network and a nationwide retail pharmacy chain. The company emphasizes innovation in biotechnology and maintains modern production facilities to support its diverse product lines. By integrating R&D with a robust logistics and retail infrastructure, it provides a wide range of healthcare solutions to medical institutions and consumers.

Recent filings

Filing Released Lang Actions
关于股东部分股份解押及质押的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the partial release and new pledging of shares by a major shareholder (the controlling shareholder) of the company. It details the number of shares pledged and released, the pledgees (banks), the purpose of the pledges (financing and credit enhancement), and confirms no major risks or violations. It also includes financial data of the controlling shareholder but does not contain comprehensive financial statements or detailed financial performance of the company itself. The document is a typical disclosure of share pledge transactions by a major shareholder, which fits the category of Transaction in Own Shares (POS). The document length is 3531 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the correct classification is POS.
2021-01-28 Chinese
2020年度非公开发行股票预案（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled "深圳市海王生物工程股份有限公司 2020 年度非公开发行股票预案" which translates to "Shenzhen Neptunus Bioengineering Co., Ltd. 2020 Non-public Issuance of Shares Proposal." The content describes a detailed plan for a non-public issuance of A shares, including background, purpose, issuance price, number of shares, use of proceeds, and approval status. It discusses the company's capital structure, financing needs, and the relationship with the controlling shareholder who will subscribe to the shares. The document is a comprehensive proposal related to capital raising through a non-public share issuance, not a general annual or interim report, nor an announcement of voting results or management changes. It is not a brief announcement but a detailed plan document. Therefore, the filing type corresponds to Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as non-public share issuance plans.
2021-01-28 Chinese
关于非公开发行完成后深圳海王集团股份有限公司将股权质押比率降低的承诺
Capital/Financing Update Classification · 95% confidence The document is a short announcement (716 characters) regarding a commitment by the controlling shareholder to reduce the pledge ratio of shares after a non-public share issuance. It includes specific details about share subscription and pledge reduction but does not contain financial statements or detailed financial data. It is not a full report but an announcement related to capital structure changes and shareholder commitments. Therefore, it fits best under Capital/Financing Update (CAP).
2021-01-28 Chinese
关于2020年度非公开发行股票预案修订情况说明的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding revisions to the 2020 non-public stock issuance plan by Shenzhen Haiwang Bioengineering Co., Ltd. It details updates to the issuance plan, including changes in issuance quantity, fundraising limits, and related contractual amendments. The document references approvals by the board and shareholders, regulatory requirements by the China Securities Regulatory Commission, and risk disclosures related to the issuance. The content focuses on capital raising activities and changes to the company's capital structure rather than financial results or management discussions. The document length is 2275 characters, which is relatively short and primarily an announcement of changes to a financing plan rather than a full detailed report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2021-01-28 Chinese
关于公司非公开发行股票申请文件二次反馈意见的回复
Capital/Financing Update Classification · 95% confidence The document is a detailed response to regulatory feedback from the China Securities Regulatory Commission regarding a non-public stock issuance application by Shenzhen Haier Bioengineering Co., Ltd. It includes extensive financial data, risk disclosures, and legal compliance information related to the stock issuance and shareholder structure. The content focuses on the company's capital raising activities, shareholder commitments, and financial assurances related to the issuance. This aligns with the category of Capital/Financing Update (CAP), as it provides updates and detailed explanations about the company's fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial and operational details, not merely an announcement or certification. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-01-28 Chinese
关于为控股子公司提供担保实施情况的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the provision of guarantees by the parent company for its subsidiaries' financing activities. It lists multiple guarantee contracts, amounts, counterparties, and terms related to credit facilities and factoring financing. The content focuses on the company's guarantee obligations and related contractual details rather than financial results, management changes, or legal proceedings. It is not an annual or interim financial report, earnings release, or management discussion. It is also not a proxy statement, voting result, or merger announcement. The document is a regulatory announcement about guarantees provided, which is a type of capital/financing update. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-01-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.